GeneCentric Therapeutics Inc.
02/08/2023 | Press release | Archived content
8th Annual Biomarker & Companion Diagnostics Conference – Feb. 8-9, 2023 | San Diego, CA
GeneCentric is a proud sponsor of the 8th Annual MarketsandMarkets Biomarker & Companion Diagnostics Conference to be held February 8-9, 2023 in San Diego, CA. Experts from academia and industry will present new information on cancer biomarker validation for clinical applications, biomarkers and personalized medicine, the impact of big data in translational biomarker research, the future of companion diagnostics, and the latest updates on regulatory guidelines and approvals. Learn more and register here.
Speaker:
Mike Milburn, PhD | GeneCentric President & CEO
Topic: The Future of RNA Diagnostics in Cancer
February 9, 2023 | 11:15am PT
- While DNA mutation and alteration status is an important biomarker for cancer therapies, newRNA expression tests offer several key advantages for companion diagnostics
- The explosive growth of RNA whole transcriptome clinical assays can be used to power new and more informative gene expression tests
- Adoption of RNA expression tests as companion diagnostics will require close collaboration with drug developers and diagnostic clinical utility studies
GeneCentric Therapeutics Inc. published this content on February 08, 2023, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 17, 2026 at 05:29 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]